 Welcome to the 14th edition of the Biopharm and Healthcare Summit. We miss you. This is a unique situation. We wished we could have met you face to face, but I guess this is the situation. First of all, I want to thank all of our sponsors. Without them, this would not have been possible, especially Biogen, Takita, Merck, Acorn MediData, Bear, Jensen, Jubilant Life Sciences, EMD Sorano, Alexion, and CRISPR. Thank you all so much for all the help you have given us over there. We are all going through unprecedented times. Every nation, rich or poor, has faced human suffering, loss of life, and economic hardship due to COVID-19 pandemic. We feel that this is a global health crisis which requires global solution. We've been saying for years now, disease has no boundaries, no nationality, no color, no religion. This is a global problem, and we think we need a global solution. It's tough for all of us, but we need to stay positive and motivated. And we are very confident that the extensive efforts of all of our colleagues, which have been working worldwide, either for the vaccines or for the therapeutics, which should be safe and have good efficacy will yield results, and hopefully we will have some solution very soon. Till that folks, hang in there. Life will be okay soon. Very important fact, which we were discussing for all these couple of weeks and months has been, whatever comes up, I think the excess and the portability is very important. Vaccines or therapeutics should go to folks who need them. It should not be based on who is rich or who is poor over there. We have a great group of leaders in the summit today from all over the world. Confident, good ideas, good strategies will emerge. What we discussed today will positively impact patients worldwide. Coming to India, it's a great opportunity for India in the current situation to play a critical role in the biopharma R&D and manufacturing in the current scenario. We have global leaders in this group today, and we have also the key policymakers and industry leaders from India. I also hope that good ideas will emerge between this discussion and it will be helpful for the patients worldwide and for patients in India. In this group today, some of them and many of our colleagues have been impacted or affected personally by the COVID. They are okay now and we wish them speedy recovery. It's really overwhelming that they're still able to participate in this meeting and be there with us. You may have noticed the calls, the panels are 40 minutes short. It's important to know that the folks in the room must spend more time actually preparing for these panels than for the 40 minutes over there. I want to thank our advisable members and all of you for your active support. I would say, stay safe and healthy till we get a vaccine. We are also very privileged and honored to have Andy Plum. Andy has been a solid rock solid supporter. He's a true believer and a very committed individual for this group and for the patients and he believes in it over there. This would be his fifth year as an EMC and I must tell you, like I've been telling you for years now, it's not an easy task. It's a lot of time commitment, but he is the one who is always a phone call away. He will never say no. So I really want to thank him and please welcome Andy Plum.